Polatuzumab Vedotin (Polivy) for DLBCL - Details


( Last Updated : May 6, 2021)
Generic Name:
Polatuzumab Vedotin
Project Status:
Active
Therapeutic Area:
Diffuse large B-cell lymphoma (DLBCL)
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Polivy
Project Line:
Reimbursement Review
Project Number:
PC0227-000
NOC Date:

Details


Tumour Type:
Lymphoma
Indications:
Diffuse Large B-Cell Lymphoma (DLBCL)
Funding Request:
Polatuzumab vedotin, in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who are not eligible for autologous stem cell transplant and have received at least one prior therapy.
Review Status:
Notification to Implement Issued
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Funding Request:
Polatuzumab vedotin, in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who are not eligible for autologous stem cell transplant and have received at least one prior therapy.
pERC Meeting:
Final Recommendation Issued: